Amgen Inc.
AMGNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. With a market capitalization of $237.48B, it sits in mega-cap territory. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEP.
Market Cap
$237.48B
Beta
0.41
P/E (TTM)
27.28
P/E (Fwd)
17.94
EPS (TTM)
$16.10
EPS (Fwd)
$24.49
ROE
91.5%
ROA
8.7%
Cash
$13.99B
Total Debt
$57.30B
Free CF
$8.65B
52W Change
50.9%
Annual Financials
Cash vs Debt
Where AMGN stands vs its 150-day and 200-day moving averages
As of the October 1, 2026 close, AMGN finished 14.80% above its 150-day moving average ($367.17) and 17.06% above its 200-day moving average ($360.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMGN overbought or oversold?
At the October 1, 2026 close, AMGN's RSI(14) was 76.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Amgen Inc. carries $57.30B in total debt against $13.99B in cash reserves — debt is roughly 4.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $8.65B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 91.5%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $26.32B (2022) to $36.75B (2025), reflecting a 40% increase over the period.
AMGN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Amgen Inc.'s trajectory.